ReviewJournal of neuro-oncology2025
Modulating the glioma microenvironment with laser interstitial thermal therapy: mechanisms and therapeutic implications.
Review in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Laser interstitial thermal therapy in pediatric neurosurgery: a prospective nationwide study on indications, safety, and early outcomes.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Article
- Spinal laser interstitial thermal therapy for treatment of chordoma: single-center experience and literature review.Journal of neuro-oncology · 2026Review
- Laser Interstitial Thermal Therapy for High-Grade Gliomas: Current Evidence, Clinical Applications and Emerging Role of Artificial Intelligence.Journal of clinical medicine · 2026Review
- Integrating Endovascular Drug Delivery into the Therapeutic Landscape of Glioblastoma.Cancers · 2026Review
- Butterfly gliomas: to biopsy or to ablate - a longitudinal cohort study.Journal of neuro-oncology · 2026Article
- Glioblastoma: current challenges and future horizons.Singapore medical journal · 2026Article
- Evolving Landscape of Glioblastoma Research: Integrating Therapeutic Advances and Diagnostic Frontiers.Brain sciences · 2026Review
- Review
- Precision Immunotherapeutics for Glioblastoma: Current Approaches and Emerging Strategies in 2026.Cells · 2026Review
- Endogenous immune recruitment in glioblastoma CAR T therapy: cytokine, myeloid, and chemokine circuitry.Journal of neuro-oncology · 2026Review
- Nexus of IDO1/Kynurenine Pathway to T-Cell Exhaustion: Hypoxia-Induced Tryptophan Metabolism in Glioblastoma.Metabolites · 2026Review
- When Central Tolerance Fails: Thymic Malignancies at the Intersection of Cancer Immunity and Autoimmunity.Cancers · 2026Review
- Biomarkers for predicting immunotherapy response and resistance in glioblastoma.Frontiers in immunology · 2026Review
- Diagnostic imaging and emerging image-guided neurointervention in brain tumors: a narrative review.Frontiers in radiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) remains one of the most deadly brain tumors through its invasiveness, rapid growth, its immunosuppressive microenvironment, and limited treatment options. Laser interstitial thermal therapy (LITT) is an MR-guided, minimally invasive ablation technique increasingly used in GBM management. This narrative review examines how LITT modulates the glioma microenvironment and explores its therapeutic implications. We cover both preclinical and clinical studies and synthesize the effects of LITT on immune activation, blood-brain barrier (BBB) permeability, and thermal dynamics in gliomas. LITT generates three spatially distinct thermal zones, promoting damage-associated molecular pattern (DAMP) release, immune cell activation, and transient BBB disruption. These changes may help convert immunologically "cold" gliomas into "hot" tumors and enhance the delivery of chemotherapy, immunotherapy, and viral or gene-based therapies. Technical limitations, such as the heat sink effect near vascular structures, are increasingly addressed through innovations like dual-fiber systems and advanced thermal modeling. LITT is emerging as much more than a cytoreductive tool for unresectable glioma; it may provide a platform for immune modulation and therapeutic enhancement in glioma care. Potential benefits of LITT's interaction with the microenvironment and the BBB include: (1) recruitment and mobilization of the immune system to better target cancerous cells; (2) improved penetration of existing therapies; (3) which enables a lower effective dose for previously barred-drugs, reducing peripheral adverse effects; (4) improved potential for peripheral liquid biopsy. Optimizing treatment timing, patient selection, and combination protocols will be essential to fully harness LITT's biological effects and improve clinical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.